Sexually transmitted disease rapid diagnostic test Aptima®

Trichomonas vaginalis

Trichomonas vaginalis (TV) is the most common curable sexually transmitted infection (STI) in the United States and accounts for more STI cases than chlamydia and gonorrhea combined.1 When left untreated, TV can lead to adverse health outcomes including reproductive complications and risk for concurrent infections.2-3 With 2.6 million TV infections in the United States, a highly sensitive nucleic acid amplification test (NAAT) like the Aptima Trichomonas vaginalis assay is key for diagnosing and treating infections.1,4-5 Achieve the Right Diagnosis When symptomatic, TV can present similarly to other STIs, making accurate diagnosis critical for informed treatment decisions.6-7 Detect up to 100% of TV Infections8 All women seeking care for vaginal discharge should be tested for TV.2 The Aptima Trichomonas vaginalis assay identifies infections missed by traditional methods.9 Guard Against Long-term Health Consequences TV infection is associated with a variety of adverse outcomes that could be prevented with early and accurate detection.2 NAAT is CDC and ACOG recommended for diagnosis of TV.5,10 Multitest Diagram As the first FDA-cleared NAAT for TV, the Aptima Trichomonas vaginalis assay is an rRNA-based NAAT that offers up to 100% sensitivity.8 NAAT assays can overcome challenges associated with traditional, less sensitive methodologies such as: Wet mount relies on detecting motile forms, leading to potential false negatives, and delayed testing reduces accuracy as trichomonas motility decreases over time.11 Variability in clinician skills affects accuracy of wet mount especially as non-motile forms may be confused with vaginal cells.12